Guided by a multidisciplinary scientific committee comprised of clinical and research experts I-O Optimise…
I-O Optimise aims to deliver valuable insights that may help:
The delivery of insights began in 2017, with regular updates over the long term as the treatment landscape evolves further. Over time, it should be possible to compare different populations and healthcare systems.
*I-O Optimise is generating data for non-small cell lung cancer, small cell lung cancer and malignant pleural mesothelioma.